title: [Isoprostanes: new markers of oxidative stress in human diseases].
abstract: BACKGROUND
  Most of the traditional methods used to assess oxidative stress in clinical setting are non specific, unreliable or inaccurate. Recently, a novel family of prostaglandin F2 isomers, called F2-isoprostanes, produced in vivo by a free radical peroxidation of arachidonic acid, has been described. These compounds may produce physiological or pathological effects due to their ability to alter smooth muscle and platelet functions. The quantification of the two major isoforms (isoprostaglandin F2 alpha type-III and VI) in biological fluids and tissues as markers of lipid peroxidation appears to be an important advance in our ability to explore the role of free radicals in the pathogenesis of human disease.
  
  
  METHODS
  Urinary excretion of F2-isoprostanes is correlated with age, indicating increased oxidative stress during the normal aging process. High F2-isoprostanes concentration has been described in diseases such as ischemic heart disease, diabetes, Alzheimer's disease and hepatic cirrhosis. The correlation of F2-isoprostane concentrations and human diseases severity in hepatic cirrhosis, cardiac failure and diabetes suggest that these compounds may be of interest as predictive markers.
  
  
  CONCLUSIONS
  Preliminary studies suggest the use of F2-isoprostanes as prognosis markers. In addition, F2-isoprostanes quantification offers promising potential as intermediate endpoints for clinical studies of antioxidant therapies.
authors.affiliation: Laboratoire de Pharmacologie, Faculté de Médecine de Grenoble, La Tronche. Jean-LucCracowski@ujf-grenoble.fr
authors.forename: J L
authors.initials: JL
authors.lastname: Cracowski
authors.forename: F
authors.initials: F
authors.lastname: Stanke-Labesque
authors.forename: C
authors.initials: C
authors.lastname: Souvignet
authors.forename: G
authors.initials: G
authors.lastname: Bessard
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000975:Antioxidants / Q000627:therapeutic use; D015415:Biomarkers; D002318:Cardiovascular Diseases / Q000378:metabolism; D002648:Child; D003920:Diabetes Mellitus / Q000378:metabolism; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000032:analysis / Q000502:physiology; D005260:Female; D005609:Free Radicals; D006801:Humans; D006937:Hypercholesterolemia / Q000378:metabolism; D007231:Infant, Newborn; D016030:Kidney Transplantation; D015227:Lipid Peroxidation; D008107:Liver Diseases / Q000378:metabolism; D008171:Lung Diseases / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000378:metabolism; D018384:Oxidative Stress / Q000502:physiology*; D011379:Prognosis; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects
chemical_list: D000975:Antioxidants; D015415:Biomarkers; D005609:Free Radicals; D015237:Dinoprost